Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Opportunistic Journals in the Clinical Pharmacology Space: A Policy Statement From the Publications and Public Policy Committees of the American College of Clinical Pharmacology.

Greenblatt DJ, Bertino JS Jr.

J Clin Pharmacol. 2018 May;58(5):567-571. doi: 10.1002/jcph.1130. No abstract available.

PMID:
29677401
2.

Opportunistic Journals in the Clinical Pharmacology Space: A Policy Statement From the Publications and Public Policy Committees of the American College of Clinical Pharmacology.

Greenblatt DJ, Bertino JS Jr.

Clin Pharmacol Drug Dev. 2018 May;7(4):353-357. doi: 10.1002/cpdd.466. No abstract available.

PMID:
29677400
3.

Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach.

Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Aubrey Stoch S, Bertino JS Jr, Nafziger AN, Ma JD.

J Clin Pharmacol. 2018 Apr 17. doi: 10.1002/jcph.1125. [Epub ahead of print]

PMID:
29663428
4.

The Journal of Clinical Pharmacology, Clinical Pharmacology in Drug Development, and the Impact Factor.

Bertino JS Jr, Greenblatt DJ.

Clin Pharmacol Drug Dev. 2017 May;6(3):218-219. doi: 10.1002/cpdd.359. No abstract available.

PMID:
28475820
5.

The Journal of Clinical Pharmacology, Clinical Pharmacology in Drug Development, and the Impact Factor.

Bertino JS Jr, Greenblatt DJ.

J Clin Pharmacol. 2017 May;57(5):545-546. doi: 10.1002/jcph.909. No abstract available.

PMID:
28409839
6.

S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.

Chang AT, Bertino JS Jr, Nafziger AN, Kashuba AD, Turpault S, Lewis LD, Ma JD.

Ther Drug Monit. 2016 Jun;38(3):383-7. doi: 10.1097/FTD.0000000000000277.

PMID:
26818625
7.

Measles Vaccine: Time to Stop the Madness.

Bertino JS Jr.

J Clin Pharmacol. 2016 Feb;56(2):141-2. doi: 10.1002/jcph.654. No abstract available.

PMID:
26780486
8.

Therapeutic drug monitoring of antibiotics.

Bertino JS Jr.

Lancet Infect Dis. 2014 Dec;14(12):1180-1. doi: 10.1016/S1473-3099(14)70988-0. Epub 2014 Nov 17. No abstract available.

PMID:
25455984
9.

The clopidogrel conundrum.

Bertino JS Jr.

J Clin Pharmacol. 2014 Aug;54(8):841-2. doi: 10.1002/jcph.344. No abstract available.

PMID:
25044099
10.

Endogenous 4β-hydroxycholesterol-to-cholesterol ratio is not a validated biomarker for the assessment of CYP3A activity.

Ma JD, Nafziger AN, Bertino JS Jr.

Drug Metab Dispos. 2013 Nov;41(11):1972. doi: 10.1124/dmd.113.054361. No abstract available.

11.

1961: from there to here: The Journal of Clinical Pharmacology and a new editor.

Bertino JS Jr.

J Clin Pharmacol. 2014 Jan;54(1):1-2. doi: 10.1002/jcph.204. No abstract available.

PMID:
24127245
12.

Validating phenotyping cocktails: more work needs to be done.

Ma JD, Nafziger AN, Bertino JS Jr.

J Clin Pharmacol. 2012 Nov;52(11):1772-3; author reply 1774-5. doi: 10.1177/0091270011436346. No abstract available.

PMID:
23105127
13.

Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity.

Wu JC, Nafziger AN, Bertino JS Jr, Ma JD.

Drug Metab Lett. 2012 Jun 1;6(2):94-101.

PMID:
22594566
14.

The not so "ideal" body weight-based dosing of Integrilin in obesity.

Pai MP, Nafziger AN, Bertino JS Jr.

Am Heart J. 2012 Apr;163(4):e23; author reply e25. doi: 10.1016/j.ahj.2012.01.032. Epub 2012 Mar 13. No abstract available.

PMID:
22520549
15.

Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.

Segreti J, Jones RN, Bertino JS Jr.

J Ocul Pharmacol Ther. 2012 Feb;28(1):3-11. doi: 10.1089/jop.2011.0072. Epub 2011 Oct 14. Review.

PMID:
21999341
16.

Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients.

Pai MP, Nafziger AN, Bertino JS Jr.

Antimicrob Agents Chemother. 2011 Sep;55(9):4006-11. doi: 10.1128/AAC.00174-11. Epub 2011 Jun 13.

17.

Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.

Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sörgel F, Jones RN, Drusano GL, Bertino JS Jr.

Diagn Microbiol Infect Dis. 2010 Nov;68(3):251-8. doi: 10.1016/j.diagmicrobio.2010.06.012. Epub 2010 Sep 18.

PMID:
20851549
18.

Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.

Ma JD, Tsunoda SM, Bertino JS Jr, Trivedi M, Beale KK, Nafziger AN.

Clin Pharmacokinet. 2010 Apr;49(4):223-37. doi: 10.2165/11318000-000000000-00000. Review.

PMID:
20214407
19.

Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants.

Gaedigk A, Jaime LK, Bertino JS Jr, Bérard A, Pratt VM, Bradfordand LD, Leeder JS.

Front Pharmacol. 2010 Oct 4;1:121. doi: 10.3389/fphar.2010.00121. eCollection 2010.

20.

Besifloxacin ophthalmic suspension for bacterial conjunctivitis.

Nafziger AN, Bertino JS Jr.

Drugs Today (Barc). 2009 Aug;45(8):577-88. doi: 1396675/dot.2009.45.8.1396675. Review.

PMID:
19927224
21.

Desirudin dosing and monitoring in moderate renal impairment.

Nafziger AN, Bertino JS Jr.

J Clin Pharmacol. 2010 Jun;50(6):614-22. doi: 10.1177/0091270009350626. Epub 2009 Nov 13.

PMID:
19915180
22.
23.

Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.

Bertino JS, Zhang JZ.

Expert Opin Pharmacother. 2009 Oct;10(15):2545-54. doi: 10.1517/14656560903213413. Review.

PMID:
19743941
24.

Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping.

Ma JD, Nafziger AN, Mylott W, Haughey DB, Rocci ML Jr, Bertino JS Jr.

Br J Clin Pharmacol. 2009 Mar;67(3):374-5. doi: 10.1111/j.1365-2125.2008.03361.x. Epub 2008 Dec 12. No abstract available.

25.

Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe.

Ma JD, Lawendy NM, Fullerton T, Snyder PJ, Nafziger AN, Bertino JS Jr.

Int J Clin Pharmacol Ther. 2009 Feb;47(2):111-9.

PMID:
19203567
26.

Utility and application of urine drug testing in chronic pain management with opioids.

Nafziger AN, Bertino JS Jr.

Clin J Pain. 2009 Jan;25(1):73-9. doi: 10.1097/AJP.0b013e31817e13cc. Review.

PMID:
19158549
27.

Quantitative assessment of hepatic blood flow using intravenous indocyanine green.

Ma JD, Nafziger AN, Mylott W, Haughey DB, Rocci ML Jr, Bertino JS Jr.

Eur J Clin Pharmacol. 2008 Nov;64(11):1133-4. doi: 10.1007/s00228-008-0519-1. Epub 2008 Jul 2. No abstract available.

PMID:
18594801
28.

Pharmacodynamics of uniform versus nonuniform warfarin dosages.

Hameed MS, Nafziger AN, Gartung AM, Bertino JS Jr.

Pharmacotherapy. 2008 Jun;28(6):707-11. doi: 10.1592/phco.28.6.707.

PMID:
18503398
29.

An evaluation of the atkins' diet.

Miller BV, Bertino JS, Reed RG, Burrington CM, Davidson LK, Green A, Gartung AM, Nafziger AN.

Metab Syndr Relat Disord. 2003 Dec;1(4):299-309. doi: 10.1089/1540419031361426.

PMID:
18370655
30.

Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis.

Nafziger AN, Bertino JS Jr.

Clin Pharmacol Ther. 2007 Oct;82(4):379; author reply 380. Epub 2007 Feb 28. No abstract available.

PMID:
17851579
31.

Back to the future: using aminoglycosides again and how to dose them optimally.

Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A.

Clin Infect Dis. 2007 Sep 15;45(6):753-60. Epub 2007 Aug 8. Review.

PMID:
17712761
32.

American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process.

Bertino JS Jr, Greenberg HE, Reed MD; American College of Clinical Pharmacology.

J Clin Pharmacol. 2007 Apr;47(4):418-22. No abstract available.

PMID:
17389550
33.

Sex differences in CYP3A activity using intravenous and oral midazolam.

Chen M, Ma L, Drusano GL, Bertino JS Jr, Nafziger AN.

Clin Pharmacol Ther. 2006 Nov;80(5):531-8.

PMID:
17112809
34.

Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors.

Fine RL, Chen J, Balmaceda C, Bruce JN, Huang M, Desai M, Sisti MB, McKhann GM, Goodman RR, Bertino JS Jr, Nafziger AN, Fetell MR.

Clin Cancer Res. 2006 Oct 1;12(19):5770-6.

35.
36.

Severe hepatotoxicity of telithromycin.

Bertino JS.

Ann Intern Med. 2006 Sep 19;145(6):472; author reply 472. No abstract available.

PMID:
16983140
37.

Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.

Chen YC, Gotzkowsky SK, Nafziger AN, Kulawy RW, Rocci ML Jr, Bertino JS Jr, Kashuba AD.

Br J Clin Pharmacol. 2006 Aug;62(2):187-95.

38.

Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin.

Kim MJ, Nafziger AN, Kashuba AD, Kirchheiner J, Bauer S, Gaedigk A, Bertino JS Jr.

Eur J Clin Pharmacol. 2006 Jun;62(6):431-6. Epub 2006 Apr 27.

PMID:
16758259
39.

Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.

Johnson BM, Song IH, Adkison KK, Borland J, Fang L, Lou Y, Berrey MM, Nafziger AN, Piscitelli SC, Bertino JS Jr.

J Clin Pharmacol. 2006 May;46(5):577-87.

PMID:
16638741
40.

Comparison of midazolam and simvastatin as cytochrome P450 3A probes.

Chung E, Nafziger AN, Kazierad DJ, Bertino JS Jr.

Clin Pharmacol Ther. 2006 Apr;79(4):350-61. Epub 2006 Feb 28.

PMID:
16580903
41.

Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.

Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS Jr.

Antimicrob Agents Chemother. 2006 Apr;50(4):1222-7.

43.

Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults.

Zhang Y, Kim MJ, Bertino JS Jr, Nafziger AN, Sellers EM.

J Clin Pharmacol. 2006 Mar;46(3):345-52.

PMID:
16490811
44.

Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam.

Ma JD, Nafziger AN, Rhodes G, Liu S, Bertino JS Jr.

Drug Metab Dispos. 2006 May;34(5):783-5. Epub 2006 Feb 7.

45.

Prospective evaluation of the treatment and outcome of community-acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals.

Davydov L, Ebert SC, Restino M, Gardner M, Bedenkop G, Uchida KM, Bertino JS Jr.

Diagn Microbiol Infect Dis. 2006 Apr;54(4):267-75. Epub 2006 Feb 8.

PMID:
16466891
47.

The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe.

Ma JD, Nafziger AN, Rhodes G, Liu S, Gartung AM, Bertino JS Jr.

J Clin Pharmacol. 2006 Jan;46(1):103-8.

PMID:
16397289
48.

Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.

Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, Sellers E, Kearns G, Leeder JS, Gaedigk A, Bertino JS Jr.

J Clin Pharmacol. 2005 Dec;45(12):1413-21.

PMID:
16291717
49.

Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered.

Lee LS, Nafziger AN, Bertino JS Jr.

Clin Pharmacol Ther. 2005 Jul;78(1):1-6. Review. No abstract available.

PMID:
16003286
50.

Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product.

Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML Jr, Bertino JS Jr.

J Clin Pharmacol. 2005 Jun;45(6):614-9.

PMID:
15901742

Supplemental Content

Loading ...
Support Center